Streamlining GLP-1 Drug Development from Synthesis to Testing
Fuelled by the global surge in type 2 diabetes and obesity, the GLP-1 market is set to explode from $20 billion in 2024 to $50 billion by 2030, offering vast opportunities for innovation. This webinar provides a deep dive into the latest advancements and best practices in GLP-1 drug development, covering the journey from early discovery synthesis, biology modelling to in-vitro and in vivo testing, and fostering a vibrant exchange of insights between academia and industry.
We’ll also explore the shift from daily-multiple to once-weekly dosing, innovations in extended dosing regimens and dual/triple agonisms, and the potential of oral formulations. Join us to uncover interdisciplinary strategies in Biology, Chemistry, and DMPK that are shaping the future of GLP-1 drug development, highlighted through real-world case studies.
What you will learn
- The evolution of GLP-1 therapies: Emphasizing the transition from daily-multiple injections to once-weekly injections, significantly boosting patient compliance.
- The Trajectory of GLP-1 Drug Development: Discussing advancements such as longer circulation, innovations in dual/triple agonisms, new indication explorations, and the potential of oral formulations.
- In-vitro Assays: Development of in-vitro assays specifically designed for the bioanalysis of GLP-1 agonists and antagonists.
- Disease Models: Exploration of NASH/MASH, Diabetes, and Diet-Induced Obesity (DIO) models.
- Synthesis Strategies: Comparative insights into Solid Phase Synthesis and Liquid Phase Synthesis for GLP-1R.
- Synthetic and Testing Differences: Insights into peptide vs. small-molecule GLP-1R agonists in both synthesis and testing fields.
- ADME and PK of Polypeptides: comprehensive analysis of in vitro ADME properties and in vivo pharmacokinetic profiles.
- Real-World Case Studies: discover best practices in Biology, Chemistry, and DMPK fields.
Speakers
